Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3263-3270

  Sader, Helio S ^a   Rhomberg, Paul R ^a   Farrell, David J ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CLINDAMYCIN; COLISTIN; DAPTOMYCIN; GENTAMICIN; HABEKACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; DIBEKACIN;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; BROTH DILUTION; DISEASE PREDISPOSITION; DRUG ACTIVITY; DRUG POTENCY; ENDOTRACHEAL TUBE; ENTEROBACTER; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL PATIENT; HUMAN; KLEBSIELLA; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPUTUM; STAPHYLOCOCCUS AUREUS; TRACHEAL ASPIRATION PROCEDURE; UNITED STATES; VENTILATOR ASSOCIATED PNEUMONIA; ANALOGS AND DERIVATIVES; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PNEUMONIA;

AMIKACIN; ANTI-BACTERIAL AGENTS; DIBEKACIN; ENTEROBACTER; HUMANS; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; PNEUMONIA; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TOBRAMYCIN;

EID: 84929590110     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04839-14     Document Type: Article

References (24)

1. Watanabe T, Goi H, Hara T, Sugano T, Tanaka Y, Kazuno Y, Matsuhashi Y, Yamamoto H, Yokota T. 1987. Antibacterial activities of arbekacin, a new aminoglycoside antibiotic, against methicillin-cephemresistant Staphylococcus aureus. Jpn J Antibiot 40:349-356.
2. Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, Lee CS. 2013. The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary study. Infect Chemother 45:62-68. http://dx.doi.org/10.3947/ic.2013.45.1.62.
3. Matsumoto T, Hanaki H, Kimura T, Nemoto M, Higashihara M, Yokota H, Oda S, Akiyama N, Miyao N, Yoshida M, Yukioka T, Soma K, Ohyashiki K, Suzuki Y, Arai T, Ikegami K, Ichiwata T, Otsuka Y, Kobayashi M, Totsuka K, Sunakawa K, ABK Dose Finding Study Group. 2013. Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study. J Infect Chemother 19:128-137. http://dx.doi.org/10.1007/s10156-012-0519-z.
4. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. 1999. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 43:727-737.
5. Hamada Y, Tamura K, Koyama I, Kuroyama M, Yago K, Sunakawa K. 2011. Clinical efficacy of arbekacin for Gram-negative bacteria. J Infect Chemother 17:876-879. http://dx.doi.org/10.1007/s10156-011-0262-x.
6. Nakamura I, Yamaguchi T, Tsukimori A, Sato A, Fukushima S, Matsumoto T. 2015. New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 34:83-87. http://dx.doi.org/10.1007/s10096-014-2192-x.
7. Zapor MJ, Barber M, Summers A, Miller GH, Feeney LA, Eberly LE, Wortmann G. 2010. In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center. Antimicrob Agents Chemother 54:3015-3017. http://dx.doi.org/10.1128/AAC.01173-09.
8. Ouchi S, Aoki M, Kamiyabu S, Vutikullird A, Gorfried M, Ishihama T. 2014. Safety, tolerability, systemic and pulmonary pharmacokinetics of ME100 inhalation solution in healthy volunteers. Abstr 54th Intersci Conf Antimicrob Agents Chemother, September 5 to 9, 2014, Washington, DC. http://www.icaac.org/.
9. Funatsu Y, Hasegawa N, Fujiwara H, Namkoong H, Asami T, Tasaka S, Kimizuka Y, Kamata H, Ishii M, Iketani O, Ogata H, Iwata S, Betsuyaku T. 2014. Pharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteers. J Infect Chemother 20:607-611. http://dx.doi.org/10.1016/j.jiac.2014.05.007.
10. Yamamoto Y, Izumikawa K, Hashiguchi K, Fukuda Y, Kobayashi T, Kondo A, Inoue Y, Morinaga Y, Nakamura S, Imamura Y, Miyazaki T, Kakeya H, Yanagihara K, Kohno S. 2012. The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection. J Infect Chemother 18:241-246. http://dx.doi.org/10.1007/s10156-012-0397-4.
11. Sader HS, Farrell DJ, Flamm RK, Jones RN. 2014. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized with pneumonia in United States and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 43:328-334. http://dx.doi.org/10.1016/j.ijantimicag.2014.01.007.
12. Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. 2013. Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother 57:3012-3020. http://dx.doi.org/10.1128/AAC.02252-12.
13. Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Clinical and Laboratory Standards Institute. 2014. M100-S24. Performance standards for antimicrobial susceptibility testing, 24th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
15. EUCAST. 2014. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0. http://www.eucast.org/clinical-breakpoints/. Accessed 15 January 2014.
16. American Thoracic Society, Infectious Disease Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416. http://dx.doi.org/10.1164/rccm.200405-644ST.
17. Jones RN. 2010. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51(Suppl 1):S81-S87. http://dx.doi.org/10.1086/653053.
18. Torres A, Ewig S, Lode H, Carlet J, European HAP working group. 2009. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 35:9-29. http://dx.doi.org/10.1007/s00134-008-1336-9.
19. Quon BS, Goss CH, Ramsey BW. 2014. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc 11:425-434. http://dx.doi.org/10.1513/AnnalsATS.201311-395FR.
20. Ioannidou E, Siempos II, Falagas ME. 2007. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 60:1216-1226. http://dx.doi.org/10.1093/jac/dkm385.
21. Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ, Nebulized Antibiotics Study Group. 2011. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa.Am J Respir Crit Care Med 184:106-115. http://dx.doi.org/10.1164/rccm.201011-1894OC.
22. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. 2008. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 32:450-454. http://dx.doi.org/10.1016/j.ijantimicag.2008.05.016.
23. Zavascki AP, Carvalhaes CG, Picao RC, Gales AC. 2010. Multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 8:71-93. http://dx.doi.org/10.1586/eri.09.108.
24. Arnold HM, Sawyer AM, Kollef MH. 2012. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 57:1226-1233. http://dx.doi.org/10.4187/respcare.01556.